2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …
The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes …
F Cosentino, PJ Grant, V Aboyans… - European heart …, 2020 - academic.oup.com
Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …
exercising their clinical judgment, as well as in the determination and the implementation of …
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …
Authors/Task Force Members:… - European journal of …, 2022 - Wiley Online Library
Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …
2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with …
2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart
Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection …
Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection …
Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European Association of Cardiovascular …
Nearly half of all patients with heart failure (HF) have a normal left ventricular (LV) ejection
fraction (EF) and the condition is termed heart failure with preserved ejection fraction …
fraction (EF) and the condition is termed heart failure with preserved ejection fraction …
How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association …
Making a firm diagnosis of chronic heart failure with preserved ejection fraction (HFpEF)
remains a challenge. We recommend a new stepwise diagnostic process, the 'HFA–PEFF …
remains a challenge. We recommend a new stepwise diagnostic process, the 'HFA–PEFF …
Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association …
Heart failure with preserved ejection fraction (HFpEF) represents a highly heterogeneous
clinical syndrome affected in its development and progression by many comorbidities. The …
clinical syndrome affected in its development and progression by many comorbidities. The …
Basic mechanisms of diabetic heart disease
Diabetes mellitus predisposes affected individuals to a significant spectrum of
cardiovascular complications, one of the most debilitating in terms of prognosis is heart …
cardiovascular complications, one of the most debilitating in terms of prognosis is heart …
Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial
Background: Chronic kidney disease and type 2 diabetes are independently associated with
heart failure (HF), a leading cause of morbidity and mortality. In the FIDELIO-DKD …
heart failure (HF), a leading cause of morbidity and mortality. In the FIDELIO-DKD …
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
AJ Scheen - Nature reviews endocrinology, 2020 - nature.com
The management of type 2 diabetes mellitus (T2DM) is becoming increasingly complex.
Sodium–glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic …
Sodium–glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic …